Intraaortic balloon support for myocardial infarction with cardiogenic shock

Area of Science:

• Cardiology
• Critical Care Medicine
• Interventional Cardiology

Background:

• Intra-aortic balloon counterpulsation (IABP) is a guideline-recommended treatment for cardiogenic shock complicating acute myocardial infarction.
• Current evidence primarily stems from registry data, with limited randomized clinical trials.
• The IABP-SHOCK II trial aimed to provide robust evidence on IABP's efficacy in this critical patient population.

Purpose of the Study:

• To evaluate the effectiveness of intra-aortic balloon counterpulsation (IABP) in reducing 30-day all-cause mortality in patients with cardiogenic shock complicating acute myocardial infarction.
• To assess the impact of IABP on secondary clinical outcomes and safety in this patient group.

Main Methods:

• A randomized, prospective, open-label, multicenter trial involving 600 patients with cardiogenic shock complicating acute myocardial infarction.
• Patients were assigned to either intraaortic balloon counterpulsation (IABP group, n=301) or no IABP (control group, n=299).
• All patients received early revascularization and optimal medical therapy; the primary endpoint was 30-day all-cause mortality.

Main Results:

• No significant difference in 30-day all-cause mortality between the IABP group (39.7%) and the control group (41.3%) was observed (P=0.69).
• Secondary endpoints, including hemodynamic stabilization, ICU length of stay, and renal function, showed no significant variations between groups.
• Rates of major bleeding, peripheral ischemic complications, sepsis, and stroke were similar in both the IABP and control groups.

Conclusions:

• Intra-aortic balloon counterpulsation (IABP) does not significantly reduce 30-day mortality in patients experiencing cardiogenic shock due to acute myocardial infarction when an early revascularization strategy is employed.
• The findings suggest a re-evaluation of IABP's role as a standard treatment in this specific clinical scenario is warranted based on this high-quality randomized trial data.